PPARD and metabolic dysfunction-associated steatotic liver disease: In a mouse model of NAFLD (Nonalcoholic fatty liver disease), GW501516, a specific PPARβ/δ ligand, inhibited the activation of NLRP3, NLRP6, and NLRP10 and decreased the production of pro-inflammatory molecules induced by high fat diet and LPS [90].